Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Intangibles (2016 - 2025)

Ligand Pharmaceuticals' Intangibles history spans 15 years, with the latest figure at $266.6 million for Q4 2024.

  • For Q4 2024, Intangibles fell 11.0% year-over-year to $266.6 million; the TTM value through Dec 2024 reached $266.6 million, down 11.0%, while the annual FY2024 figure was $266.6 million, 11.0% down from the prior year.
  • Intangibles for Q4 2024 was $266.6 million at Ligand Pharmaceuticals, down from $274.9 million in the prior quarter.
  • Across five years, Intangibles topped out at $595.3 million in Q4 2020 and bottomed at $206.5 million in Q1 2020.
  • The 5-year median for Intangibles is $329.6 million (2023), against an average of $382.7 million.
  • The largest annual shift saw Intangibles surged 182.89% in 2020 before it tumbled 39.1% in 2023.
  • A 5-year view of Intangibles shows it stood at $595.3 million in 2020, then tumbled by 36.73% to $376.7 million in 2021, then fell by 9.09% to $342.5 million in 2022, then fell by 12.51% to $299.6 million in 2023, then fell by 11.0% to $266.6 million in 2024.
  • Per Business Quant, the three most recent readings for LGND's Intangibles are $266.6 million (Q4 2024), $274.9 million (Q3 2024), and $283.2 million (Q2 2024).